Pharmaceutical

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

TCR therapies are minimally engineered and can target both cell surface antigens and intracellular antigens.

Aug 11, 2024 - 04:00
Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval
TCR therapies are minimally engineered and can target both cell surface antigens and intracellular antigens.
Read the original article

Tags:

Previous Article

AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

Next Article

Gilead Sciences reports net income rise in Q2 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

API Chemical Contract Manufacturing Companies for the Pharmaceutical Industry

API Chemical Contract Manufacturing Companies for the P...

Sep 28, 2024

Phase III study halted: Ferrer’s oral edaravone disappoints in ALS

Phase III study halted: Ferrer’s oral edaravone disappo...

Jan 31, 2024

Opinion: PAs need a new name, but ‘physician associate’ won’t cut it. Here’s a better idea

Opinion: PAs need a new name, but ‘physician associate’...

Jun 2, 2023